Institutional demand and economic uncertainty fuel the historic rally in the world's largest cryptocurrency, pushing the market into a bullish frenzy.
Pharmaceuticals, heavy trucks, and furniture targeted in a move that could spark fresh inflation fears and impact corporate profits.
The approval of the twice-daily pill remibrutinib positions the company to challenge injectable treatments in a multi-billion dollar market.
Late-breaking trial results for obefazimod show significant efficacy, positioning the first-in-class oral therapy in a competitive market.
The ongoing US government shutdown is delaying critical jobs and inflation reports, creating an information vacuum for investors and the Federal Reserve.
Combination therapy approval for small cell lung cancer offers a new standard of care and a bullish signal for the pharmaceutical sector.
First-of-its-kind maintenance therapy approved for extensive-stage small cell lung cancer, a historically difficult-to-treat malignancy.
The designation for ALTO-101 targets cognitive impairment, a debilitating aspect of schizophrenia with no currently approved treatments.